Premium
Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma
Author(s) -
Kröger Nicolaus,
Krüger William,
Renges Helmut,
Zabelina Tatjana,
Stute Norbert,
Jung Roman,
Wittkowsky Georg,
Kuse Rolf,
Zander Axel Rolf
Publication year - 2001
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2001.02599.x
Subject(s) - medicine , multiple myeloma , donor lymphocyte infusion , immunosuppression , lymphocyte , hematopoietic stem cell transplantation , graft versus host disease , immunofixation , transplantation , disease , gastroenterology , surgery , immunology , monoclonal , antibody , monoclonal antibody
Two patients with persistent disease after allografting for multiple myeloma received donor T‐cell lymphocyte infusion (DLI) (1·5 × 10 8 and 7 × 10 7 ) to induce a graft‐vs.‐myeloma effect for further tumour regression after withdrawal of immunosuppression. The interval between stem cell transplantation and DLI was 8 and 14 months respectively. Both patients converted from partial to complete remission, lasting 12+ and 28+ months. Immunofixation became negative after 3 and 4 months. The main toxicity was grade II and III acute graft‐vs.‐host disease (GvHD) and limited or extensive chronic GvHD in each patient. We conclude that DLI induced further tumour reduction in patients with persistent disease after allografting for multiple myeloma.